These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21276939)

  • 1. Dihydroisoxazole analogs for labeling and visualization of catalytically active transglutaminase 2.
    Dafik L; Khosla C
    Chem Biol; 2011 Jan; 18(1):58-66. PubMed ID: 21276939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2.
    Choi K; Siegel M; Piper JL; Yuan L; Cho E; Strnad P; Omary B; Rich KM; Khosla C
    Chem Biol; 2005 Apr; 12(4):469-75. PubMed ID: 15850984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationship analysis of the selective inhibition of transglutaminase 2 by dihydroisoxazoles.
    Watts RE; Siegel M; Khosla C
    J Med Chem; 2006 Dec; 49(25):7493-501. PubMed ID: 17149878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of potent and specific dihydroisoxazole inhibitors of human transglutaminase 2.
    Klöck C; Herrera Z; Albertelli M; Khosla C
    J Med Chem; 2014 Nov; 57(21):9042-64. PubMed ID: 25333388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of transglutaminase activity using click chemistry.
    van Geel R; Debets MF; Löwik DW; Pruijn GJ; Boelens WC
    Amino Acids; 2012 Sep; 43(3):1251-63. PubMed ID: 22180026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and evaluation of gluten peptide analogs as selective inhibitors of human tissue transglutaminase.
    Hausch F; Halttunen T; Mäki M; Khosla C
    Chem Biol; 2003 Mar; 10(3):225-31. PubMed ID: 12670536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversible and competitive cinnamoyl triazole inhibitors of tissue transglutaminase.
    Pardin C; Roy I; Lubell WD; Keillor JW
    Chem Biol Drug Des; 2008 Sep; 72(3):189-96. PubMed ID: 18715232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irreversible inhibitors of tissue transglutaminase.
    Keillor JW; Chabot N; Roy I; Mulani A; Leogane O; Pardin C
    Adv Enzymol Relat Areas Mol Biol; 2011; 78():415-47. PubMed ID: 22220480
    [No Abstract]   [Full Text] [Related]  

  • 9. An unprecedented dual antagonist and agonist of human Transglutaminase 2.
    Yi MC; Palanski BA; Quintero SA; Plugis NM; Khosla C
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4922-4926. PubMed ID: 26004580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acylideneoxoindoles: a new class of reversible inhibitors of human transglutaminase 2.
    Klöck C; Jin X; Choi K; Khosla C; Madrid PB; Spencer A; Raimundo BC; Boardman P; Lanza G; Griffin JH
    Bioorg Med Chem Lett; 2011 May; 21(9):2692-6. PubMed ID: 21215619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of carbon-11 labeled acryl amides for selective PET imaging of active tissue transglutaminase.
    van der Wildt B; Wilhelmus MM; Bijkerk J; Haveman LY; Kooijman EJ; Schuit RC; Bol JG; Jongenelen CA; Lammertsma AA; Drukarch B; Windhorst AD
    Nucl Med Biol; 2016 Apr; 43(4):232-42. PubMed ID: 27067043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Progress in the Development of Transglutaminase 2 (TGase2) Inhibitors.
    Song M; Hwang H; Im CY; Kim SY
    J Med Chem; 2017 Jan; 60(2):554-567. PubMed ID: 28122456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis.
    Chrobok NL; Bol JGJM; Jongenelen CA; Brevé JJP; El Alaoui S; Wilhelmus MMM; Drukarch B; van Dam AM
    PLoS One; 2018; 13(4):e0196433. PubMed ID: 29689097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photolabeling of tissue transglutaminase reveals the binding mode of potent cinnamoyl inhibitors.
    Pardin C; Roy I; Chica RA; Bonneil E; Thibault P; Lubell WD; Pelletier JN; Keillor JW
    Biochemistry; 2009 Apr; 48(15):3346-53. PubMed ID: 19271761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transglutaminase as a therapeutic target for celiac disease.
    Sulic AM; Kurppa K; Rauhavirta T; Kaukinen K; Lindfors K
    Expert Opin Ther Targets; 2015 Mar; 19(3):335-48. PubMed ID: 25410283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies towards in vivo imaging of active transglutaminase type 2 using positron emission tomography.
    van der Wildt B; Lammertsma AA; Drukarch B; Windhorst AD
    Amino Acids; 2017 Mar; 49(3):585-595. PubMed ID: 27380031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of transglutaminase 2 in celiac disease pathogenesis.
    Klöck C; Diraimondo TR; Khosla C
    Semin Immunopathol; 2012 Jul; 34(4):513-22. PubMed ID: 22437759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substrates, inhibitors, and probes of mammalian transglutaminase 2.
    Zhuang R; Khosla C
    Anal Biochem; 2020 Feb; 591():113560. PubMed ID: 31874171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transglutaminase 2 undergoes a large conformational change upon activation.
    Pinkas DM; Strop P; Brunger AT; Khosla C
    PLoS Biol; 2007 Dec; 5(12):e327. PubMed ID: 18092889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inspired by Nature: The 3-Halo-4,5-dihydroisoxazole Moiety as a Novel Molecular Warhead for the Design of Covalent Inhibitors.
    Pinto A; Tamborini L; Cullia G; Conti P; De Micheli C
    ChemMedChem; 2016 Jan; 11(1):10-4. PubMed ID: 26607551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.